Tuotekehitysputki

Kehitysputkessa olevat hoidot

Tutkimus- ja kehitysryhmiemme tavoitteena on löytää aivosairauksien taustalla olevat mekanismit. Kuljemme yhdessä kohti tavoitetta kehittää ja tarjota uusia hoitomuotoja, jotka edistävät potilaiden hoidon standardeja sekä osoittavat ne aivosairauksien alueet, joissa on suurimmat kehitystarpeet.

Hormonal / neuropeptide signaling

Circuitry / neuronal biology

Protein aggregation, folding and clearance

Neuroinflammation / Neuroimmunology

CGRP: Calcitonin gene-related peptide;
Two phase III clinical trials, supporting registration in Asia, including China and Japan: SUNRISE, and SUNSET trials.
PACAP: Pituitary adenylate cyclase activating peptide;
ACTH: Adrenocorticotropic hormone. Two phase Ib trials are currently ongoing in Congenital Adrenal Hyperplasia and Cushing’s Disease. For technical reasons, the latter has been officially categorized as a Phase II trial to adhere to local requirements in Georgia;
Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors;
Post-traumatic stress disorder;
Dopamine receptor D1 and D2;
MAGLi: Monoacylglycerol lipase (“MAGlipase”) inhibitor;
Ph1b trial ongoing in TED (Thyroid Eye Disease)